Paul King

Dr. Paul King

Monash University and Monash Medical Centre, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2015 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
PKPaul King
Paul King
Chronic obstructive pulmonary disease (COPD) is characterized by lung inflammation that persists after smoking cessation. This inflammation is heterogeneous but the key inflammatory cell types involved are macrophages, neutrophils and T cells. Other lung cells may also produce inflammatory mediators, particularly the epithelial cells. The main inflammatory mediators include tumor necrosis factor alpha, interleukin‐1, interleukin‐6, reactive oxygen species and proteases. COPD is also associated with systemic inflammation and there is a markedly increased risk of cardiovascular disease (particularly coronary artery disease) and lung cancer in patients with COPD. There is strong associative evidence that the inflammatory cells/mediators in COPD are also relevant to the development of cardiovascular disease and lung cancer. There are a large number of potential inhibitors of inflammation in COPD that may well have beneficial effects for these comorbidities. This is a not well‐understood area and there is a requirement for more definitive clinical and mechanistic studies to define the relationship between the inflammatory process of COPD and cardiovascular disease and lung cancer.

1 December 2006 in Respiratory Medicine
Verified
Journal Article
Closed access
PKPaul King
Paul King
SHStephen R. Holdsworth
Stephen R. Holdsworth
NFNicholas J. Freezer
Nicholas J. Freezer
EVElmer Villanueva
Elmer Villanueva
PHPeter W. Holmes
Peter W. Holmes

1 October 2009 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
PKPaul King
Paul King
The pathophysiology of bronchiectasis Paul T KingDepartment of Medicine, Department of Respiratory and Sleep Medicine, Monash University, Monash Medical Centre, Melbourne, Victoria, Australia Bronchiectasis is defined by permanent and abnormal widening of the bronchi. This process occurs in the context of chronic airway infection and inflammation. It is usually diagnosed using computed tomography scanning to visualize the larger bronchi. Bronchiectasis is also characterized by mild to moderate airflow obstruction. This review will describe the pathophysiology of noncystic fibrosis bronchiectasis. Studies have demonstrated that the small airways in bronchiectasis are obstructed from an inflammatory infiltrate in the wall. As most of the bronchial tree is composed of small airways, the net effect is obstruction. The bronchial wall is typically thickened by an inflammatory infiltrate of lymphocytes and macrophages which may form lymphoid follicles. It has recently been demonstrated that patients with bronchiectasis have a progressive decline in lung function. There are a large number of etiologic risk factors associated with bronchiectasis. As there is generally a long-term retrospective history, it may be difficult to determine the exact role of such factors in the pathogenesis. Extremes of age and smoking/chronic obstructive pulmonary disease may be important considerations. There are a variety of different pathogens involved in bronchiectasis, but a common finding despite the presence of purulent sputum is failure to identify any pathogenic microorganisms. The bacterial flora appears to change with progression of disease. Keywords: bronchiectasis, inflammation, obstructive lung disease, pathophysiology, pathology

1 August 2007 in Respiratory Medicine
Verified
Journal Article
Closed access
PKPaul King
Paul King
SHStephen R. Holdsworth
Stephen R. Holdsworth
NFNicholas J. Freezer
Nicholas J. Freezer
EVElmer Villanueva
Elmer Villanueva
PHPeter W. Holmes
Peter W. Holmes

14 June 2012 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
PKPaul King
Paul King
Haemophilus influenzae is present as a commensal organism in the nasopharynx of most healthy adults from where it can spread to cause both systemic and respiratory tract infection. This bacterium is divided into typeable forms (such as type b) or nontypeable forms based on the presence or absence of a tough polysaccharide capsule. Respiratory disease is predominantly caused by the nontypeable forms (NTHi). Haemophilus influenzae has evolved a number of strategies to evade the host defense including the ability to invade into local tissue. Pathogenic properties of this bacterium as well as defects in host defense may result in the spread of this bacterium from the upper airway to the bronchi of the lung. This can result in airway inflammation and colonization particularly in chronic obstructive pulmonary disease. Treatment of respiratory tract infection with Haemophilus influenzae is often only partially successful with ongoing infection and inflammation. Improvement in patient outcome will be dependent on a better understanding of the pathogenesis and host immune response to this bacterium.

1 January 2005 in COPD: Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Closed access
PKPaul King
Paul King
SHStephen R. Holdsworth
Stephen R. Holdsworth
NFNicholas J. Freezer
Nicholas J. Freezer
EVElmer Villanueva
Elmer Villanueva
MGMartin Gallagher
Martin Gallagher
PHPeter W. Holmes
Peter W. Holmes
The outcome in adult bronchiectasis has not been well described; in particular there has been a lack of long-term prospective studies. Therefore a follow-up study was performed to assess outcome in...